- Home
- VRTX vs PLD Comparison
VRTX vs PLD Comparison
Compare VRTX & PLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRTX
- PLD
- Stock Information
- Founded
- VRTX 1989
- PLD 1983
- Country
- VRTX United States
- PLD United States
- Employees
- VRTX N/A
- PLD N/A
- Industry
- VRTX EDP Services
- PLD Real Estate Investment Trusts
- Sector
- VRTX Technology
- PLD Real Estate
- Exchange
- VRTX Nasdaq
- PLD Nasdaq
- Market Cap
- VRTX 96.6B
- PLD 105.6B
- IPO Year
- VRTX 1991
- PLD 1994
- Fundamental
- Price
- VRTX $410.82
- PLD $114.54
- Analyst Decision
- VRTX Buy
- PLD Buy
- Analyst Count
- VRTX 25
- PLD 18
- Target Price
- VRTX $493.64
- PLD $121.81
- AVG Volume (30 Days)
- VRTX 1.7M
- PLD 3.3M
- Earning Date
- VRTX 11-03-2025
- PLD 10-15-2025
- Dividend Yield
- VRTX N/A
- PLD 3.48%
- EPS Growth
- VRTX N/A
- PLD 21.80
- EPS
- VRTX 14.07
- PLD 3.70
- Revenue
- VRTX $11,418,800,000.00
- PLD $8,914,974,000.00
- Revenue This Year
- VRTX $10.90
- PLD $1.51
- Revenue Next Year
- VRTX $9.57
- PLD $6.00
- P/E Ratio
- VRTX $29.16
- PLD $31.37
- Revenue Growth
- VRTX 10.46
- PLD 10.01
- 52 Week Low
- VRTX $362.50
- PLD $85.35
- 52 Week High
- VRTX $519.88
- PLD $127.65
- Technical
- Relative Strength Index (RSI)
- VRTX 61.10
- PLD 62.12
- Support Level
- VRTX $400.74
- PLD $113.11
- Resistance Level
- VRTX $411.91
- PLD $118.20
- Average True Range (ATR)
- VRTX 8.84
- PLD 1.81
- MACD
- VRTX 3.92
- PLD 0.11
- Stochastic Oscillator
- VRTX 97.78
- PLD 71.45
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
About PLD Prologis Inc.
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1.3 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $60 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.